Arrowhead Pharmaceuticals (ARWR) Current Assets (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Current Assets data on file, last reported at $1.8 billion in Q1 2026.

• Quarterly Current Assets rose 62.06% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 62.06% YoY) and the FY2025 annual result came in at $950.6 million, up 36.69% from the prior year.
• Current Assets advanced to $1.8 billion in Q1 2026, from $1.2 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $1.8 billion in Q1 2026 to a low of $237.9 million in Q4 2023.
• A 5-year average of $696.1 million and a median of $570.5 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2023 — Current Assets slumped 58.63% — and 2024, when it jumped 139.82%.
• Tracing ARWR's Current Assets over 5 years: stood at $575.0 million in 2022, then tumbled by 58.63% to $237.9 million in 2023, then soared by 139.82% to $570.5 million in 2024, then soared by 105.84% to $1.2 billion in 2025, then jumped by 56.66% to $1.8 billion in 2026.
• The last three Current Assets figures came in at $1.8 billion (Q1 2026), $1.2 billion (Q4 2025), and $950.6 million (Q3 2025), per Business Quant data.